<DOC>
	<DOCNO>NCT00696995</DOCNO>
	<brief_summary>This study conduct Europe . The aim observational study evaluate incidence serious adverse drug reaction initiate switch insulin therapy NovoMix® 30 subject type 2 diabetes normal clinical practice condition</brief_summary>
	<brief_title>An Observational Study Type 2 Diabetes Patients Starting NovoMix® 30 Treatment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Patients Type 2 diabetes Insulinnaive previously treat basal insulin therapy Patients unlikely comply protocol Pregnancy breastfeed intention become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>